Literature DB >> 11375897

Analysis of potential biomarkers of estrogen-initiated cancer in the urine of Syrian golden hamsters treated with 4-hydroxyestradiol.

R Todorovic1, P Devanesan, S Higginbotham, J Zhao, M L Gross, E G Rogan, E L Cavalieri.   

Abstract

Estrone (E1) and 17beta-estradiol (E2) are metabolized to catechol estrogens (CE), which may be oxidized to semiquinones and quinones (CE-Q). CE-Q can react with glutathione (GSH) and DNA, or be reduced to CE. In particular, CE-3,4-Q react with DNA to form depurinating adducts (N7Gua and N3Ade), which are cleaved from DNA to leave behind apurinic sites. We report the determination of 22 estrogen metabolites, conjugates and adducts in the urine of male Syrian golden hamsters treated with 4-hydroxyestradiol (4-OHE2). After initial purification, urine samples were analyzed by HPLC with multichannel electrochemical detection and by capillary HPLC/tandem mass spectrometry. 4-Hydroxyestrogen-2-cysteine [4-OHE1(E2)-2-Cys] and N-acetylcysteine [4-OHE1(E2)-2-NAcCys] conjugates, as well as the methoxy CE, were identified and quantified by HPLC, whereas the 4-OHE1(E2)-1-N7Gua depurinating adducts and 4-OHE1(E2)-2-SG conjugates could only be identified by the mass spectrometry method. Most of the administered 4-OHE2 was metabolically converted to 4-OHE1. Formation of thioether (GSH, Cys and NAcCys) conjugates and depurinating adducts [4-OHE1(E2)-1-N7Gua] indicates that oxidation of 4-CE to CE-3,4-Q and subsequent reaction with GSH and DNA, respectively, do occur. The major conjugates in the urine were 4-OHE1(E2)-2-NACCYS: The oxidative pathway of 4-OHE1(E2) accounted for approximately twice the level of products compared with those from the methylation pathway. The metabolites and methoxy CE were excreted predominantly (>90%) as glucuronides, whereas the thioether conjugates were not further conjugated. These results provide strong evidence that exposure to 4-OHE1(E2) leads to the formation of E1(E2)-3,4-Q and, subsequently, depurinating DNA adducts. This process is a putative tumor initiating event. The estrogen metabolites, conjugates and adducts can be used as biomarkers for detecting enzymatic oxidation of estrogens to reactive electrophilic metabolites and possible susceptibility to estrogen-induced cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375897     DOI: 10.1093/carcin/22.6.905

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry.

Authors:  J Embrechts; F Lemière; W Van Dongen; E L Esmans; P Buytaert; E Van Marck; M Kockx; A Makar
Journal:  J Am Soc Mass Spectrom       Date:  2003-05       Impact factor: 3.109

2.  Metabolomic applications of electrochemistry/mass spectrometry.

Authors:  Paul H Gamache; David F Meyer; Michael C Granger; Ian N Acworth
Journal:  J Am Soc Mass Spectrom       Date:  2004-12       Impact factor: 3.109

3.  Estrogen carcinogenesis: specific identification of estrogen-modified nucleobase in breast tissue from women.

Authors:  Qiang Zhang; Rebecca L Aft; Michael L Gross
Journal:  Chem Res Toxicol       Date:  2008-08-02       Impact factor: 3.739

4.  Formation of two novel estrogen guanine adducts and HPLC/MS detection of 4-hydroxyestradiol-N7-guanine in human urine.

Authors:  Leslie A Bransfield; Alissa Rennie; Kala Visvanathan; Shelly-Ann Odwin; Thomas W Kensler; James D Yager; Marlin D Friesen; John D Groopman
Journal:  Chem Res Toxicol       Date:  2008-06-27       Impact factor: 3.739

5.  Urinary estrogen metabolites and prostate cancer risk: a pilot study.

Authors:  Ourania Kosti; Xia Xu; Timothy D Veenstra; Ann W Hsing; Lisa W Chu; Lenka Goldman; Ionut Bebu; Sean Collins; Anatoly Dritschilo; John H Lynch; Radoslav Goldman
Journal:  Prostate       Date:  2010-09-30       Impact factor: 4.104

6.  Ultrafiltration tandem mass spectrometry of estrogens for characterization of structure and affinity for human estrogen receptors.

Authors:  Yongkai Sun; Chungang Gu; Xuemei Liu; Wenzhong Liang; Ping Yao; Judy L Bolton; Richard B van Breemen
Journal:  J Am Soc Mass Spectrom       Date:  2005-02       Impact factor: 3.109

7.  Efficient synthesis, liquid chromatography purification, and tandem mass spectrometric characterization of estrogen-modified DNA bases.

Authors:  Qiang Zhang; Michael L Gross
Journal:  Chem Res Toxicol       Date:  2008-05-31       Impact factor: 3.739

8.  Reduction of estrogen-induced transformation of mouse mammary epithelial cells by N-acetylcysteine.

Authors:  Divya Venugopal; Muhammad Zahid; Paula C Mailander; Jane L Meza; Eleanor G Rogan; Ercole L Cavalieri; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2007-12-07       Impact factor: 4.292

9.  Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer.

Authors:  Chun Huang; Xuan Wang; Baocun Sun; Man Li; Xiulan Zhao; Yanjun Gu; Yanfen Cui; Yan Li
Journal:  Target Oncol       Date:  2014-05-17       Impact factor: 4.493

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.